NephroPlus reports strong Q1FY27 results with 23.7% YoY revenue growth to ₹281.8 Cr and 30.7% YoY Adj. EBITDA growth to ₹65.1 Cr. Treatments rose 13.3%, and network expanded to 550 clinics across 5 countries.
Nephroplus dispatches annual report with AGM notice, providing web link to shareholders. Shares available on company & exchange websites. Updates on KYC encouraged.
NephroPlus cancels participation in the HSBC Singapore Conference due to unavoidable circumstances.
NephroPlus reports strong FY26 results with revenue up 32.2% YoY to ₹998.8 Cr and adjusted EBITDA climbing 37.6% to ₹238.1 Cr, driven by increased treatments and international market growth.
